doi:10.1136/bjsports-2017-097608 Areta JL, Burke LM, Ross ML, et al
doi: 10.1016/j.neulet.2016.02.011
Some newer agents permit less frequent dosingfor example, retatrutide and certain long-acting formulations may allow biweekly or monthly administration
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
By the way, finasteride is primarily aimed at treating male-pattern baldness, and ZipHealth classifies it under its Men section, but it may have some utility for women
doi:10.1111/jhn.12090 Manor I, Magen A, Keidar D, et al